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The reciprocal translocation involving chromosomes 15 and 17 [t(15;17) (q22;q21)] is associated with acute promyelocytic leukemia (APL) and leads to the fusion of the retinoic acid receptor α (RARα ) and promyelocytic leukemia (PML) genes thus generating the PML/RARα hybrid gene. 1 The use of all-trans retinoic acid (ATRA) and anthracyclinebased chemotherapy represents the mainstay in treatment of APL, inducing complete hematological and molecular remission in a high proportion of patients. [2] [3] [4] ATRA induces the malignant cells to differentiate into phenotypically mature myeloid cells, and prompt resolution of the characteristic coagulopathy of APL. In vitro, the differentiation process induced by ATRA has been associated with increased expression of integrins, cytokine release, and changes in cellular rheology. [5] [6] [7] [8] More recently, arsenic trioxide (ATO) has been included in the armamentarium of active drugs in APL, being perhaps the most active single agent. 9 ATO at lower doses induces myeloid differentiation, whereas in higher doses it induces apoptosis.
Although ATRA and ATO are well tolerated, approximately one fourth of the patients develop the differentiation syndrome (DS), formerly known as Retinoid Acid Syndrome. DS was first described by Frankel et al (1992) , 10 who detected this syndrome in nine of 35 (25%) newly diagnosed APL patients. Symptoms occurred after 2 to 21 days of treatment and were generally associated with increasing white blood cell (WBC) count and combined fever, weight gain, dyspnea, pleural effusion, and pulmonary infiltrates on chest radiograph and, in some patients, renal failure, hypotension, and pericardial effusion. Six percent to 27% of APL patients develop DS, and mortality rates range from 1% to 7%. [11] [12] [13] Our group analyzed 71 APL patients treated with ATRA + anthracycline and observed a DS incidence of 11.26%, with an average time for syndrome development of 11.5 days after starting ATRA treatment and a mortality rate of 12.5%. 14 Taken together, the data in literature reinforce the importance of early diagnosis, since DS responds well to dexamethasone treatment (10 mg twice daily for at least 3 days). Interestingly, the results from the European APL Group trials suggested that, besides corticosteroids, chemotherapy concomitant to ATRA reduced the incidence of the syndrome, although there was no clear reduction in the related mortality rate. 15 As mentioned above, DS is also seen with ATO treatment. Twenty-three percent of the APL patients in the US multicenter trial 16 developed DS. All of these patients also had leukocytosis and were treated with dexamethasone without any deaths and without interruptions in the administration of arsenic trioxide.
Several cellular and molecular mechanisms participate in DS development ( Figure 1 ). ATRA induces a variety of effects in APL cells in vitro, including increased production of interleukin-1 beta (IL-1β), 6, 17 IL-8, 6 receptors for granulocyte colony-stimulating factor (G-CSF) 18 and granulocyte-macrophage colony-stimulating factor (GM-CSF). 19 Changes in the expression of cell-surface integrins, such as LFA-1 (CD11a/CD18) and Mac-1(CD11b/CD18), also were demonstrated by different authors. 5, [20] [21] [22] Several clinical features of DS seem to be related to these observations, in particular, fever, fluid retention, and the migration of differentiating myeloid cells into extravascular tissues. 10 Extravascular migration of myeloid cells may be partly related to upregulated integrin expression, which could increase adhesion of these cells to vascular endothelium, thereby facilitating their extravasation. 20, [23] [24] Nevertheless, Brown et al. (1999) 25 have demonstrated that ATRA induced rolling of NB4 cells (an APL cell line) on endothelium through the modulation of E-selectin, without the participation of α 4 integrin and P-selectin. In addition to these molecules, intercellular adhesion molecule-1 (ICAM-1, CD54) may further contribute to DS development since adhesion of leukocytes to endothelial cells is an essential prerequisite for stable arrest and transmigration of neutrophils. In fact, levels of soluble CD54 increase in the plasma of APL patients and decrease after the APL is cured. 5 Recently, our group demonstrated a significant increase in the expression of CD11b and ICAM-1 in ATRAtreated NB4 cells, while in APL primary cells, in addition to these two markers, CD18 was also up-regulated by ATRA. 8 In the same study, ATO up-regulated ICAM-1 in NB4 cells both at 0.1 and 1 µM concentration. G-CSF treatment upregulated CD11b expression and potentiated ATRA-induced CD18 and CD11b expression on APL primary cells. Importantly, we did not detect synergism between ATRA and ATO in the upregulation of these molecules. This observation is relevant in face of the recent results of clinical trials using the combination of ATO and ATRA as front line therapy for APL. 26 The increase in CD11b, CD18 and CD54 expression was accompanied by a higher adhesion to Matrigel and to pulmonary endothelium, and was blocked by pre-incubation with dexamethasone, anti-CD54 or anti-CD18. To test the role of these adhesion molecules in vivo, CD54 or CD18 knock out mice and their wild-type controls were injected with NB4 cells and treated IP with ATRA. After sacrifice, MPO activity in the lungs was determined by colorimetric assay. These results suggest that both leukocyte and endothelial adhesion molecules are essential for DS development.
Gao et al (2007) 27 demonstrated that in addition to IL-1β and IL-8, ATRA treatment could induce the expressions of IFN-γ in APL patient blast cells. By using human umbilical cord endothelial cells (HUVECs), and human lung microvascular endothelial cells (HLMVECs), they observed that low doses of IFN-γ and IL-1β could synergistically had affirmed that patients with microgranular variant M3v of APL appear to be protected from the syndrome, but these findings had not been confirmed in posterior studies. 14 Considering the relevance of ICAM1 in leukocyte infiltration and the effect of ATRA and ATO on its expression, we decided to analyze the role of ICAM1 polymorphisms in DS development. We included PECAM-1 (platelet-endothelial cell adhesion molecule-1) polymorphisms since it is constitutively expressed by most circulating leukocytes, platelets and endothelial cells, and both adhesion molecules are involved in endothelium integrity and extravasation of cells from the blood compartment into the vessel and underlying tissue. 29 We analyzed 127 APL patients of whom 23 developed DS. Only patients with respiratory distress accompanied by pulmonary infiltrates were analyzed. Regarding age, gender, WBC counts, hemoglobin and platelets values, no predictive factor of DS development in APL patients could be found. Considering genetic variations in adhesion molecules ICAM-1 and PECAM-1 we detected no significant association between ICAM-1 G241R or PECAM-1 L125V polymorphisms and DS. On the other hand, the AA genotype at codon 469 of ICAM-1 was significantly associated to DS in APL patients. 30 The 469 E/ K polymorphism in exon 6 results in a change from glutamic acid to lysine in Ig-like domain 5 of ICAM-1, which is thought to affect interactions with LFA-1 and adhesion of B-cells. The functional effect of this polymorphism is still unclear, but it may influence disease susceptibility.
In conclusion, DS is a multifactorial process and the activation of adhesion molecules by ATRA and ATO are triggering events. Genetic determinants, such as ICAM-1 polymorphisms, may play a role in its pathogenesis and larger multicentric studies are necessary to establish the value these markers as risk factors in DS development. 
